Statutory negotiations at Orion's R&D unit in Turku, Finland have been concluded

Orion b

45.00 CHF 12.09%

• Charts
• News
• Analysen

Kaufen Verkaufen

ORION CORPORATION
PRESS RELEASE
15 April 2025 at 10.00 EEST          

        
Statutory negotiations at Orion's R&D unit in Turku, Finland have been concluded

Orion Corporation announced in a press release on 10 March 2025 that the company is establishing a new research and development centre in Cambridge, UK with a focus on biological medicines. As the company's plan is to develop biological and large-molecule therapies in Cambridge, a statutory negotiation process commenced on 7 March 2025 in accordance with the Finnish Act on Co-operation within Undertakings to assess the impacts on Orion’s Protein and Antibody Engineering & Characterization unit in Turku, Finland.

The statutory negotiations have been concluded ahead of schedule on Monday, 7 April 2025. The company has decided to wind down the operations of the Protein and Antibody Engineering & Characterization unit during the summer of 2025.

New roles within the company have been found for many employees of the discontinued organization, and fewer than 10 persons are subject to reductions following the conclusion of the negotiations.

All affected employees have been informed of the outcome.

                                                 
Contact person:
Outi Vaarala
Executive Vice President
Innovative Medicines and Research & Development
tel. +358 10?426 3472

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orionpharma.com

Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq Helsinki.